Omeros (OMER) EPS (Basic) (2010 - 2026)

Omeros (OMER) posted EPS (Basic) of $0.07 for Q1 2026, down 35.24% sequentially from $0.1 in Q4 2025, and down 5.39% YoY from $0.07 in Q1 2025.

Omeros (OMER) EPS (Basic) (2010 - 2026) Analysis & Trends

Omeros has reported EPS (Basic) for 17 years, with the latest figure at $0.07 in Q1 2026.

Quarterly EPS (Basic) fell 5.39% year-over-year to $0.07 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $0.03 (down 92.49% YoY) and the FY2025 annual result came in at $0.02, down 94.83% from the prior year.
EPS (Basic) declined to $0.07 in Q1 2026 per OMER's latest filing, from $0.1 in the prior quarter.
Over five years, EPS (Basic) peaked at $2.79 in Q4 2022 and troughed at -$0.15 in Q3 2025.
A 5-year average of $0.3 and a median of $0.1 in 2022 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2025: EPS (Basic) jumped 72.45% in 2022, then slumped 273.32% in 2025.
Over 5 years, EPS (Basic) stood at $2.79 in 2022, then tumbled by 82.71% to $0.48 in 2023, then plunged by 81.5% to $0.09 in 2024, then rose by 15.94% to $0.1 in 2025, then tumbled by 35.24% to $0.07 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered $0.07, $0.1, and -$0.15 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	12.62
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	7.59
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-3.06
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.16
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.18
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.23
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.06
10	Omeros	1.24 Bn	1.24 Bn	27.73 Mn	0.09

Download Data